Robert D Anderson1, Geoffrey Lee1, Sohaib Virk2, Richard G Bennett3, Christopher S Hayward4, Kavitha Muthiah4, Jonathan Kalman1, Saurabh Kumar5. 1. Department of Cardiology, Royal Melbourne Hospital, Faculty of Medicine, Dentistry, and Health Science, University of Melbourne, Melbourne, Australia. 2. Department of Cardiology, Westmead Hospital, Westmead, Australia. 3. Bristol Heart Institute, Bristol Royal Infirmary, Bristol, United Kingdom. 4. Heart Failure and Transplant Unit, Department of Cardiology, St. Vincent's Hospital, Darlinghurst, Australia. 5. Department of Cardiology, Westmead Hospital, Westmead, Australia; Department of Cardiology, Westmead Applied Research Centre, University of Sydney, Westmead, Australia. Electronic address: saurabh.kumar@health.nsw.gov.au.
Abstract
OBJECTIVES: This is a systematic review summarizing the procedural characteristics and outcomes of ventricular assist device (VAD)-related ventricular tachycardia (VT) ablation. BACKGROUND: Drug-refractory VT refractory commonly develops post-VAD implantation. Procedural and outcome data come from small series or case reports. METHODS: An electronic search was performed using major databases. Primary outcomes were VT recurrence, mortality, and cardiac transplantation. Secondary endpoints were acute procedural success and procedural complications. RESULTS: Eighteen studies were included, with a total of 110 patients (mean age 59.6 ± 11 years, 89% men; VT storm 34%). Scar-related re-entry was the predominant mechanism of VT (90.3%) and cannula-related VT in 19.3% cases. Electroanatomical mapping interference occurred in 1.8% of cases; there were no reports of catheter entrapment. Noninducibility of clinical VT was achieved in 77.9%; procedural complications occurred in 9.4%. At a mean follow-up of 263.5 ± 267.0 days, VT recurred in 43.6%, 23.4% underwent cardiac transplant, and 48.1% died. There were no procedural-related deaths and no death was directly related to ventricular arrhythmia. In follow-up, there was a significant reduction in implantable cardioverter-defibrillator therapies or shocks (57.1% vs. 23.8%). Ablation allowed VT storm termination in 90% of patients. CONCLUSIONS: VAD-related VT is predominantly related to pre-existing intrinsic myocardial scar rather than inflow cannula site insertion. Catheter ablation is a reasonable treatment strategy, albeit with expectedly high rate of recurrence, transplantation, and mortality related to severe underlying disease. Crown
OBJECTIVES: This is a systematic review summarizing the procedural characteristics and outcomes of ventricular assist device (VAD)-related ventricular tachycardia (VT) ablation. BACKGROUND:Drug-refractory VT refractory commonly develops post-VAD implantation. Procedural and outcome data come from small series or case reports. METHODS: An electronic search was performed using major databases. Primary outcomes were VT recurrence, mortality, and cardiac transplantation. Secondary endpoints were acute procedural success and procedural complications. RESULTS: Eighteen studies were included, with a total of 110 patients (mean age 59.6 ± 11 years, 89% men; VT storm 34%). Scar-related re-entry was the predominant mechanism of VT (90.3%) and cannula-related VT in 19.3% cases. Electroanatomical mapping interference occurred in 1.8% of cases; there were no reports of catheter entrapment. Noninducibility of clinical VT was achieved in 77.9%; procedural complications occurred in 9.4%. At a mean follow-up of 263.5 ± 267.0 days, VT recurred in 43.6%, 23.4% underwent cardiac transplant, and 48.1% died. There were no procedural-related deaths and no death was directly related to ventricular arrhythmia. In follow-up, there was a significant reduction in implantable cardioverter-defibrillator therapies or shocks (57.1% vs. 23.8%). Ablation allowed VT storm termination in 90% of patients. CONCLUSIONS: VAD-related VT is predominantly related to pre-existing intrinsic myocardial scar rather than inflow cannula site insertion. Catheter ablation is a reasonable treatment strategy, albeit with expectedly high rate of recurrence, transplantation, and mortality related to severe underlying disease. Crown
Authors: P Christian Schulze; Markus J Barten; Udo Boeken; Gloria Färber; Christian M Hagl; Christian Jung; David Leistner; Evgenij Potapov; Johann Bauersachs; Philip Raake; Nils Reiss; Diyar Saeed; David Schibilsky; Stefan Störk; Christian Veltmann; Andreas J Rieth; Jan Gummert Journal: Med Klin Intensivmed Notfmed Date: 2022-07-11 Impact factor: 1.552
Authors: Paolo Domenico Dallaglio; JuliÁn Rodríguez Garcia; Marta Aceña; Andrea Di Marco; Valentina Faga; Laia Garrido; Laia Llorca; Ignasi Anguera Journal: J Innov Card Rhythm Manag Date: 2021-01-15
Authors: Christian Sohns; Henrik Fox; Leonard Bergau; Philipp Sommer; Mustapha El Hamriti; Michel Morshuis; Denise Guckel; René Schramm; Sebastian V Rojas; Guram Imnadze; Jan F Gummert Journal: Clin Res Cardiol Date: 2021-10-28 Impact factor: 5.460